Russian Federation
UDK 61 Медицина. Охрана здоровья
A clinical case of detection of prostate cancer with multiple bone metastases is presented. It has been clearly demonstrated that oncopathology in the early stages may go unnoticed due to the absence of specific symptoms, as well as the ability to mimic other nosologies in clinical manifestations during its progression. The importance of oncological alertness on the part of the doctor is shown, the need for medical examination is once again emphasized.
prostate gland, cancer, hip joint, biopsy, prostate specific antigen, clinical examination, metastases
1. Vorob'ev A.V. Obschie voprosy skrininga. Prakticheskaya onkologiya. 2010;11(2):53-59.
2. Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a metaanalysis comparing 18FDG PET, CT, MRI and bone scintigraphy. European Radiology 2011; 21(12): 2604-2617. DOI:https://doi.org/10.1007/s00330-011-2221-4
3. Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2014 godu. M.: MNIOI im. P.A. Gercena - filial FGBU «NMIRC» Minzdrava Rossii, 2015. C. 25-27, 31, 130-133.
4. von Moos R. Costa L.Gonzalez-Suarez E.et al. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody.Cancer Treat Rev. 2019; 76: 57-67
5. Revmatologiya. Nacional'nye rekomendacii / Pod red. E.L. Nasonova, V.A. Nasonovoy. M.; 2008: 562-5.
6. Center M.M., Jemal A., Lortet-Tieulent J. et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92. 2.
7. Cooperberg M.R., Broering J.M., Carroll P.R. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2020;28: 1117-23.
8. Abbas F, Civantos F, Benedetto P, et al. Small cell carcinoma of the bladder and prostate. Urology. 1995;46(5):617-30.
9. Chughtai B, Forde J, Thomas D, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031.
10. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53(2):171-184. https://doi.org/10.1002/mnfr.200700511
11. Alyaev Yu.G., Glybochko P.V., Pushkar' D.Yu., red. Urologiya. Rossiyskie klinicheskie rekomendacii. M.: GEOTAR-Media; 2020.
12. Sidorenkov A.V., Govorov A.V., Sadchenko A.V. Diagnosticheskaya znachimost' [-2]proPSA i PHI (obzor literatury). Onkourologiya. 2014;4:87-95.
13. Chissov V.I., Alekseev B.Ya., Rusakov I.G., red. Onkourologiya. Nacional'noe rukovodstvo. M.: GEOTAR-Media; 2019.
14. Tang A, Keu Gao K, Chu L, et al. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8(14):23937-54. DOIhttps://doi.org/10.18632/oncotarget.14893.
15. Assouline-Dayan Y., Chang C., Greenspan A., Shoenfeld Y., Gershwin M.E. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94-124.
16. Kaprin A.D., Starinskiy V.V., Petrova G.V. Sostoyanie onkologicheskoy pomoschi naseleniyu Rossii v 2015 godu. M.: MNIOI im. P.A. Gercena - filial FGBU «NMIRC» Minzdrava Rossii, 2016. 236 s.
17. Chissov V.I., Rusakov I.G. Experimental & Clinical urology. Zabolevaemost' rakom predstatel'noy zhelezy v Rossiyskoy Federacii. 2011; 2-3.
18. European Association of Urology (EAU). Guidelines 2014; pp. 154-63.
19. Zaridze D.G. Profilaktika raka. Rukovodstvo dlya vrachey. Moskva, IMA-Press, 2009. 221 s.
20. Klinicheskie rekomendacii Ministerstva zdravoohraneniya Rossiyskoy Federacii «Rak predstatel'noy zhelezy». 2017. 71s.
21. CatalonaW.J., Southwick P.C., Slawin K.M. et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging // Urology. 2002. V. 56. P. 255-260.
